

Drug Utilization Review (DUR) Meeting Minutes December 3, 2013

Members Present: Norman Byers, John Savageau, Greg Pfister, Jeffrey Hostetter, Peter Woodrow, Carlotta McCleary, Carrie Sorenson, Russ Sobotta, Tanya Schmidt

Members Absent: Cheryl Huber, Todd Twogood, Leann Ness, Steve Irsfeld, James Carlson, Michael Booth, Gary Betting

Medicaid Pharmacy Department: Brendan Joyce

HID Staff Present: Candace Rieth

Chair G. Pfister called the meeting to order at 1:00 pm. Chair G. Pfister asked for a motion to approve the minutes from the September meeting. N. Byers moved that the minutes be approved, and J. Hostetter seconded the motion. Chair G. Pfister called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update

B. Joyce informed the board members that he has nothing new to share.

Board Update

The state law creating the DUR Board was reviewed with the members. Appointment to the board and term end dates were provided. Members were asked to help find replacements for their positions when their terms end. Board members were reminded that the executive director of the department may replace an appointed member of the board who fails to attend a DUR Board meeting three consecutive times without advance excuse.

Sirturo Second Review

A motion and second were made at the September meeting to place Sirturo on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Brisdelle Second Review

A motion and second were made at the September meeting to place Brisdelle on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Nitroglycerin Lingual Spray/Sublingual Tablets Second Review

A motion and second were made at the September meeting to place Nitroglycerin Lingual Spray on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Agents Used to Treat COPD Second Review

A motion and second were made at the September meeting to place agents used to treat COPD on prior authorization. The topic was brought up for a second review. After review of the data, B. Joyce recommended handling this with an age-based prior authorization (no PA required for those 40 years or older). There was no public comment. P. Woodrow made a motion to amend the original motion to state that an age-based prior authorization will be placed on these agents. G. Pfister seconded the motion. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Epinephrine Auto-Injection Devices Second Review

A motion and second were made at the September meeting to place Epinephrine Auto-Injection Devices on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Pulmozyme Second Review

A motion and second were made at the September meeting to place Pulmozyme on prior authorization. The topic was brought up for a second review. D. Evans, representing Genentech spoke regarding Pulmozyme. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Statin Review

B. Joyce reviewed statin information with the board. There was no public comment. J. Hostetter made a motion to place name-brand statins on prior authorization. G. Pfister seconded the motion. This topic will be reviewed at the next meeting.

Vecamyl Review

B. Joyce reviewed Vecamyl clinical information with the board. There was no public comment. G. Pfister made a motion to place Vecamyl on prior authorization. T. Schmidt seconded the motion. This topic will be reviewed at the next meeting.

Yearly PA Review

The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. All forms and criteria were reviewed. Changes include:

1. ACE-I/ARB/Renin Inhibitors PA form – include generic ARBs
2. Actoplus Met – add to combination form
3. Aczone – add to acne form
4. Carisoprodol and Soma 250 – combine into one form
5. Clorpress – add to combination form
6. Daliresp – add to COPD form
7. Gilenya – add specialist box on form
8. Hep C – add new products to market
9. Livalo – add to statin form
10. Narcotics/APAP – add combo products with lower APAP dose to PA criteria
11. Moxeza – add to ophthalmic anti-infective form
12. PAH – add new products to market and add Revatio
13. Provigil/Nuvigil – combine into one form
14. Solodyn – combine with Doryx and Oracea
15. Tecfidera – add neurologist on form

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. G. Pfister moved to approve the new criteria and C. Sorenson seconded the motion. Chair G. Pfister called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held March 3, in Bismarck. N. Byers made a motion to adjourn the meeting. J. Hostetter seconded. The motion passed with no audible dissent. G. Pfister adjourned the meeting.